In Brief: Psivida, Compumedics, Avantogen
22 June, 2005 by Ruth BeranPsivida (ASX:PSD) has released the full results of its Phase IIa trial of BrachySil in inoperable primary liver cancer patients, showing that the product is safe and effective in prompting tumour regression.
State governments fund research initiatives
22 June, 2005 by Susan WilliamsonSpeaking at BIO 2005 in Philadelphia, Victorian premier Steve Bracks announced a new AUD$63 million initiative to fund the new Victorian Neurotrauma Initiative (VNI).
Biosceptre diagnostic detects ovarian cancer
22 June, 2005 by Ruth BeranA study by Peptech's (ASX:PTD) joint venture partner Biosceptre has found that its diagnostic test successfully identified ovarian cancer in tissue analysis, paving the way for the development of a commercial test for this disease.
Proteome to develop TB diagnostic
22 June, 2005 by Iain ScottThe Bill Gates-funded Foundation for Innovative New Diagnostics (FIND) has called on Sydney's Proteome Systems (ASX:PXL) to develop a new diagnostic test for tuberculosis, one of the deadliest diseases in developing countries.
Study findings a no-brainer
20 June, 2005 by Graeme O'NeillA study has shown that brain shrinkage occurs only in ageing men, although cognitive performance remains constant.
Young cancer researchers recognised
17 June, 2005 by Susan WilliamsonCure Cancer Australia has announced the winners of its 2005 young researcher awards, which recognise outstanding cancer researchers in the early stages of their career.
Bionomic's epilepsy diagnostic receives positive feedback
17 June, 2005 by Graeme O'NeillThebarton (SA) epilepsy specialist Bionomics (ASX:BNO, BNOOA; US OTC:BMICY) is getting positive feedback on its newly commercialised DNA diagnostic for severe myoclonic epilepsy of infancy (SMEI).
Agenix revises loss, details ThromboView plans
07 June, 2005 by Ruth BeranBrisbane's Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has forecast a lower full year loss for the year ended June 30 of between AUD$12.3 million and $12.8 million, compared with a $14.3 million loss last year.
FDA backs IDT thalidomide facility
07 June, 2005 by Ruth BeranThe Institute of Drug Technology (ASX:IDT) has been granted US Food and Drug Administration (FDA) approval to supply commercial quantities of Thalomid (thalidomide) to its US-based global biopharmaceutical client Celgene.
National breast cancer tissue bank established
26 May, 2005 by Graeme O'NeillBreast cancer researchers and health-service agencies in NSW have formed a consortium to establish a national tissue bank, containing annotated tissues from breast cancer patients, as resource for Australian researchers.
Melbourne's HealthLinx signs assay deal with Bruker
25 May, 2005 by Graeme O'NeillMelbourne-based health-management house HealthLinx has signed a collaboration agreement with US clinical proteomics company Bruker Daltonics to develop a multiplex, in vitro diagnostic (IVD) assay for ovarian cancer.
NHMRC to establish national clinical trials register
18 May, 2005 by Ruth BeranThe National Health and Medical Research Council (NHMRC) is to spend AUD$1.5 million to establish a national clinical trials register.
New $1.1m cancer unit opens at the Garvan
17 May, 2005 by Ruth BeranThe prime minister has officially opened the Australian Cancer Research Foundation (ACRF) Unit for Molecular Genetics of Cancer at Garvan Institute of Medical Research in Sydney.
Federal budget: nothing new for biotechnology
12 May, 2005 by Ruth BeranThe federal budget, handed down on Tuesday night, makes no new commitments to science, with most of the money allocated simply honouring previous election promises.
Brain and Mind Institute receives $5 million
11 May, 2005 by Susan WilliamsonThe federal budget has allocated AUD$5 million to Sydney University's Brain and Mind Research Institute, to go towards fitting out its new premises.
